|
Found 148 result(s) FROM 1963 pages containing the term 'iatrogenic disease'.
Friday Jun 26, 2009
Gum Disease Prominent in RA, but TNF-Blockade Can Help
Three new studies shed light on the connection between rheumatoid arthritis (RA) and periodontitis, and new data help define a role for TNF-blockade in improving periodontal status as well as RA signs and symptoms...
Friday May 29, 2009
NIH Pops $24M into Orphan Diseases Research
NIH will put $24 million into a new program for developing drugs for rare and neglected diseases...
Thursday May 14, 2009
Taligen Nabs $26M for Inflammatory Disease Research
Taligen is focusing on developing anti-inflammatory drugs that affect the alternative complement pathway, which helps initiate inflammation...
Thursday Apr 23, 2009
Merck Inks Deal with Galapagos in Inflammatory Diseases
Merck and Galapagos have signed a multi-year agreement for discovery and development of new drugs for inflammatory disease...
Wednesday Mar 04, 2009
Drop of Collagenase Provides Non-Surgical Fix for Dupuytren's Disease
A nonsurgical approach using a drop of collagenase to weaken the tissue cord that causes hand contractures in Dupuytren's disease is headed for FDA review...
Thursday Jan 15, 2009
Parkinson's Disease Puts Bones, Joints at Risk
The symptoms of Parkinson’s disease—tremors, rigidity in the joints, and balance problems—can lead to reduced bone mass and a greater risk of falls, resulting in heightened numbers of bone fractures and joint injuries…
Monday Nov 17, 2008
Vitamin D Levels Linked to OA Cartilage Loss, OA Pain, and SSc Disease Activity by ACR Researchers
Low vitamin D levels are associated with faster progression of joint damage, bone loss, and pain in OA and with higher levels of inflammatory markers and vascular complications in systemic sclerosis, suggesting that more attention to vitamin D supplements might be in order...
Wednesday Nov 12, 2008
Novartis’ ACZ885 Phase III Data Show Rapid, Sustained Clinical Remission in Children and Adults with CAPS, a Group of Rare, Potentially Life-Threatening Autoinflammatory Diseases
Novartis also announced that preliminary results of a phase I/II study in systemic juvenile idiopathic arthritis showed that most patients treated with ACZ885 achieved substantial clinical improvement within 15 days...
Tuesday Oct 28, 2008
Rheumatology Experts Say Stopping Smoking May Cut RA Pain, Disease Activity
Researchers at two major medical meetings are highlighting the role smoking plays in chronic pain and disease activity in RA...
Tuesday Oct 21, 2008
Centocor Reports Efficacy of Remicade® vs Azathioprine in Treatment of Crohn’s Disease
Azathioprine is not approved in the US for the treatment of CD but is approved in some countries outside the US and is widely used by gastroenterologists and other physicians in the US to treat CD patients...
Monday Oct 20, 2008
Gleevec/CYC Combo Emerging as Novel Approach for Scleroderma Lung Disease
Adding the oncology drug imatinib (Gleevec®) to cyclophosphamide offers a 2-pronged strategy that might be effective in scleroderma-associated pulmonary complications...
Tuesday Sep 30, 2008
Microparticles May Be Big Players in Systemic Scleroderma Disease Activity
Microparticles—small, membrane, coated vesicles—found in the blood of systemic scleroderma patients might not be inert debris…
Thursday Sep 25, 2008
Disease Factors, Corticosteroids Nearly Double Heart Attack Risk in RA Patients
RA-specific factors and corticosteroid use significantly increase the risk of myocardial infarction in RA patients…
Thursday Sep 18, 2008
GSK, Cellzome Announce Strategic Alliance to Identify Kinase-Targeted Drugs for Inflammatory Diseases
The alliance gives GSK access to Cellzome’s expertise in identifying and developing selective kinase inhibitors and its proprietary Kinobeads™ technology which, by screening compounds in a physiological setting, is designed to improve the predictability of these drug candidates’ performance in clinical testing...
Tuesday Jul 22, 2008
Compugen Reports Positive Preclinical Results for Therapeutic Peptide Candidate for Immune Related Diseases
The gp96 protein triggers both the innate and adaptive arms of the immune system and is thought to play a key role in inflammatory responses, making it an important target for therapeutic intervention in the treatment of immune-related disorders...
Thursday Jun 26, 2008
Otsuka, UCB to Codevelop and Copromote Cimzia® in Japan for Crohn's Disease
UCB and Otsuka Pharmaceuticals have agreed to copromote UCB's anti-TNFα drug Cimzia® for the treatment of Crohn's Disease in Japan, the second largest pharmaceutical market in the world...
Monday Jun 09, 2008
Genta Announces Phase I Clinical Trial Results for G4544, an Oral Formulation of Gallium Nitrate, a Novel Potent Drug for Bone Disease
Results from the phase I clinical trial of G4544 showed that the drug was well-tolerated and that blood levels were achieved in a range known to be clinically bioactive...
Friday May 23, 2008
Iatrogenic Problems Reported in Low Back Pain, Osteoporosis Patients at AACE Meeting
Cases of iatrogenic Cushing's syndrome (CS) from intra-articular triamcinolone and iatrogenic hypercalcemia from combined teriparatide-hydrochlorothiazide were reported at the American Association of Clinical Endocrinologists 2008 meeting...
Monday May 19, 2008
ChemoCentryx Initiates Phase I Clinical Trial of CCR1 Inhibitor CCX354 for Inflammatory Disease; Milestone Triggers $10 Million Payment From Partner GSK
ChemoCentryx announced the initiation of a phase I clinical trial of CCX354, an orally-available, novel small molecule compound designed to specifically target the CCR1 chemokine receptor associated with inflammatory diseases...
Monday May 12, 2008
Nuon Raises $27 Million to Advance Tranilast Through Phase II Clinical Trials for Autoimmune Diseases
Nuon completed a $27 million series B financing to advance tranilast, its orally available, small-molecule lead compound...
Wednesday Apr 30, 2008
UCB Launches CIMplicity™ Program to Provide Comprehensive Treatment Support to Crohn’s Disease Patients Receiving Cimzia® (certolizumab pegol)
UCB's new CIMplicity™ program provides Cimzia® patients and their caregivers with comprehensive financial, administrative, compliance, and treatment support...
Tuesday Apr 29, 2008
Recent Advances in the Management of Crohn's Disease
Biological agents offer advances in the treatment of Crohn’s disease, while surgery and autologous stem cell transplantation may be viable options for patients with severe refractory Crohn’s…
Thursday Apr 24, 2008
UCB’s Cimzia® Approved in the US for the Treatment of Moderate-to-Severe Crohn's Disease; Dosed Subcutaneously Every 4 Weeks
The US FDA has approved Cimzia® (certolizumab pegol), indicated for reducing signs and symptoms of Crohn’s disease and maintaining clinical response in adult patients with moderate-to-severe active disease who have an inadequate response to conventional therapy...
Thursday Apr 17, 2008
PAH Differs in Connective Tissue Diseases
Patients with PAH due to connective tissue disease have more dysfunctional pulmonary capillary endothelium than those with PAH from other causes...
Thursday Apr 10, 2008
Omega-3 Free Fatty Acids for the Maintenance of Remission in Crohn’s Disease
Researchers found that omega-3 free fatty acids were not effective in preventing relapse in patients with Crohn’s disease…
Tuesday Mar 25, 2008
UCB Reports That CHMP Upholds Negative Opinion on Cimzia® (certolizumab pegol) for Crohn’s Disease
The European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) has rejected UCB's appeal to have Cimzia® (certolizumab pegol) approved for the treatment of Crohn’s disease patients...
Thursday Mar 20, 2008
Two-Pronged Strategy for Treating PAH in Lupus or Mixed Connective Tissue Disease
Lupus or MCTD patients with pulmonary arterial hypertension (PAH) should be treated with cyclophosphamide and glucocorticoids, with added pulmonary vasodilators in more severe cases...
Thursday Mar 20, 2008
Sickle Cell Bone Disease: Response to Vitamin D and Calcium
Patients with sickle cell disease should be screened for vitamin D deficiency and low bone mineral density…
Tuesday Mar 11, 2008
Will Hematopoietic Stem Cell Transplantation Cure Human Autoimmune Diseases?
Researchers analyzed hematopoietic stem cell transplantation as an acceptable therapy for autoimmune diseases…
Tuesday Mar 04, 2008
Karo Bio AB, Zydus Cadila to Develop Selective Glucocorticoid Receptor Modulators to Treat Inflammatory Diseases; Karo Reacquires Rights to SARMs From Radius
Karo Bio AB and Zydus Cadila announced a 3-year research collaboration to discover and develop novel, selective glucocorticoid receptor (GR) modulators for the treatment of inflammatory diseases...
Thursday Feb 28, 2008
Adult Stem Cells Nearing Clinical Use for RA, SLE, Other Autoimmune Diseases
Adult stem cells offer a safer, less controversial approach than embryonic stem cells to treat various rheumatoid and autoimmune diseases, and are now entering randomized clinical trials...
Thursday Feb 21, 2008
Pharmacopeia Advances Chemokine Receptor Antagonist Into Preclinical Development for Inflammatory and Autoimmune Disease Indications
Pharmacopeia Inc announced the advancement of PS031291, a potent and highly selective oral antagonist at the chemokine receptor CCR1, as a preclinical development compound from its internal CCR1 discovery program...
Thursday Jan 17, 2008
Elan, Biogen Idec Gain US FDA Approval of Tysabri® for Treatment of Moderate-to-Severe Crohn's Disease
Elan Corp, plc and Biogen Idec announced the approval of a supplemental Biologics License Application for Tysabri® (natalizumab) for inducing and maintaining clinical response and remission in adult patients with active moderate-to-severe Crohn's disease...
Monday Jan 14, 2008
Drug Approved. Is Disease Real?
As Pfizer markets Lyrica® (pregabalin), the first approved medicine to treat fibromyalgia, doctors debate the legitimacy of the pain syndrome...
Wednesday Dec 12, 2007
Ferring's Euflexxaâ„¢ (1% sodium hyaluronate) is Effective in Treating Knee OA and Reduces Pain that Interferes with ADLs; Shows Equal Effectiveness in Disease Stages Two and Three
Ferring Pharmaceuticals announced the results of two clinical studies on the efficacy of Euflexxaâ„¢, an intra-articular hyaluronic acid (IA-HA) for the relief of pain in knee osteoarthritis (OA)...
Monday Nov 19, 2007
UCB Reports that the Committee for Medicinal Products for Human Use has Denied Market Authorization in the EU for Cimzia® to Treat Crohn's Disease; UCB to Appeal
UCB Pharma SA announced that it has been informed by the European Medicines Agency that the Committee for Medicinal Products for Human Use has rejected a marketing authorization in the EU for Cimzia® (certolizumab pegol) for reducing signs and symptoms and maintaining clinical response in patients with severe, active Crohn's disease...
Thursday Nov 08, 2007
Serum Uric Acid May Be Independent Risk Factor in RA Cardiovascular Disease
Elevated serum uric acid, a potentially modifiable problem, may be an independent risk factor for cardiovascular disease in patients with RA...
Tuesday Nov 06, 2007
Cytokine PharmaSciences Develops Orally Active Form of Semapimod, a Raf Kinase Inhibitor, for Inflammatory and Autoimmune Diseases; Seeks Partner
Cytokine PharmaSciences Inc, a privately-held, global biopharmaceutical company, announced development of an orally active form of semapimod, its anti-inflammatory cytokine compound...
Wednesday Oct 24, 2007
GSK and Tolerx Form Worldwide Collaboration for Development and Commercialization of Otelixizumab (TRX4) for T-Cell Mediated Autoimmune and Inflammatory Diseases
GlaxoSmithKline and Tolerx, Inc announced a worldwide alliance to develop and commercialize otelixizumab (TRX4), a novel humanized anti-CD3 monoclonal antibody that has potential across a broad range of T-cell mediated autoimmune and inflammatory diseases including psoriasis and rheumatoid arthritis...
Friday Oct 19, 2007
Lilly Acquires Exclusive Rights to MacroGenics' Humanized Anti-CD3 Monoclonal Antibody and Will Collaborate to Develop Autoimmune Disease Treatments
Eli Lilly and Co and MacroGenics, Inc have entered into a global strategic alliance to develop and commercialize teplizumab (MGA031 or hOKT3γ1(Ala-Ala)), a humanized, non-Fc receptor binding, anti-CD3 monoclonal antibody, as well as other potential next generation anti-CD3 molecules, for use in the treatment of multiple T–cell-mediated autoimmune diseases...
Tuesday Oct 16, 2007
Ocera Completes Enrollment in Phase III Clinical Trial of AST-120 in Fistulizing Crohn's Disease
Ocera Therapeutics, Inc, a privately-held biopharmaceutical company focused on the development and commercialization of proprietary compounds to treat gastrointestinal (GI) and liver diseases, announced that it has completed patient enrollment of its double-blind, placebo-controlled phase III study in fistulizing Crohn's disease...
Thursday Oct 11, 2007
Review Rejects "Chronic Lyme Disease" Diagnosis, Extended IV Antibiotics
A major review challenges "chronic Lyme disease" as a valid diagnosis and warns against extended use of IV antibiotics...
Tuesday Oct 09, 2007
Sitaxsentan May Offer Alternative to Bosentan for PAH in Connective Tissue Disease Patients
Sitaxsentan improved 6-minute walk distance and quality of life in connective tissue disease patients who also have PAH...
Tuesday Aug 28, 2007
Diseased Blood Vessels in the Bone May Cause or Aggravate OA
Vascular pathology may play a role in the pathogenesis or progression of osteoarthritis…Findlay DM. Rheumatology. 2007; doi:10.1093/rheumatology/kem191 [Epub ahead of print].
Tuesday Aug 07, 2007
Medarex Announces Initiation by Licensing Partner Novartis of Phase III Clinical Trial for Muckle-Wells Syndrome, a Rare Inherited Autoinflammatory Disease
Medarex, Inc announced that Novartis Pharmaceuticals AG has advanced ACZ885, a fully human monoclonal antibody targeting interleukin-1β (IL-1 β), to a phase III clinical trial for Muckle-Wells syndrome (MWS), an inherited systemic autoinflammatory disease...
Friday Jul 20, 2007
OA Experts Discuss Inflammation, Joint Protection, Need for Disease-Modifying OA Drugs
CIAOMed's roundtable of osteoarthritis experts discuss the role of inflammation in OA, the possibility that OA joint damage might be preventable, and the future role of disease-modifying drugs in OA....
Thursday Jun 28, 2007
RA Disease Activity Decreases During Pregnancy, but Less Than Was Assumed
A prospective study of RA outcomes during pregnancy shows that improvement and remission rates are not as high as previously reported…
Friday Jun 15, 2007
First Phase III Tocilizumab Data Show Rapid Improvement in RA Disease Activity, Confirming Critical Role of IL-6
Results of the first phase III trial of tocilizumab show that the anti-IL-6 monoclonal combined with methotrexate produces fast, sustained improvements in RA signs and symptoms, including a notable number of DAS28 remissions...
Thursday Jun 14, 2007
More Patients Needed to Validate Biomarkers and Genotyping in Rheumatoid Diseases
Biomarkers and genotyping technology have outpaced the number of patient cohorts available for validation studies in rheumatoid diseases, but the new approaches are expected to change how clinicians assess disease susceptibility and predict response to therapy...
Monday Jun 11, 2007
Centocor's Remicade® (Infliximab) Receives EU Approval as First and Only Biologic for the Treatment of Pediatric Patients With Severe, Active Crohn's Disease
Centocor, Inc, a wholly owned subsidiary of Johnson & Johnson and Schering-Plough Corp, announced that the European Commission has approved a new indication for Remicade (infliximab) allowing for the treatment of severe, active Crohn's disease (CD) in pediatric patients ages 6 to 17 years, who have not responded to conventional therapy including a corticosteroid, an immunomodulator, and primary nutrition therapy, or who are intolerant to, or have contraindications for such therapies...
Monday Jun 11, 2007
Abbott's HUMIRA® (Adalimumab) Approved in the European Union for the Treatment of Crohn's Disease
Abbott Laboratories announced that it has received marketing authorization from the European Commission for the use of Humira® (adalimumab) as a treatment for severe Crohn's disease (CD)...
Friday May 18, 2007
Xanthus Acquires Exclusive License to FLT3 Tyrosine Kinase Pathway Patent Estate as a Target for Treating Autoimmune Diseases
Xanthus Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company that focuses on the discovery, development, acquisition, and commercialization of small-molecule therapeutics for the treatment of autoimmune diseases and cancer, announced that it has acquired an exclusive worldwide license to a patent estate from The Johns Hopkins University (JHU) for treating immune-related disorders by inhibiting the FLT3 receptor tyrosine kinase...
Thursday Apr 26, 2007
Cellerant's Allogeneic Hematopoietic Stem Cell Transplants Improve Survival and Disease Symptoms in Lupus Mouse Model
Cellerant Therapeutics Inc, a clinical-stage biotechnology company with a portfolio of products and services under development for the regulation of the hematopoietic system, announced data suggesting that established autoimmune disease can be reversed or stabilized by the transplantation of highly purified allogeneic, hematopoietic adult stem cells (HSC) in a mouse model of systemic lupus erythematosus (SLE)...
Monday Apr 16, 2007
Abbott Seeks US and EU Regulatory Approval for HUMIRA® (Adalimumab) in Psoriasis; Receives US FDA Approval in Crohn's Disease
Abbott Laboratories announced that it has simultaneously submitted a supplemental Biologics License Application (sBLA) with the US FDA and a Type II Variation to the European Medicines Agency (EMEA) seeking approval to market HUMIRA® (adalimumab) as a treatment for moderate-to-severe chronic plaque psoriasis, the fifth autoimmune disease targeted for HUMIRA therapy in both the US and Europe...
Thursday Mar 15, 2007
MIC-1 May Be a Biomarker for Erosive Disease in RA
Serum levels of the transforming growth factor ß superfamily member MIC-1 may help clinicians identify rheumatoid arthritis patients who are at greatest risk for erosive disease and thus are candidates for aggressive therapy…
Friday Mar 09, 2007
La Jolla Pharmaceutical Reports Positive Interim Antibody Results From Riquent® Lupus Phase III Trial; Results Imply Greater Probability of Clinical Benefit in the Treatment of Lupus Renal Disease as a Trial Outcome
La Jolla Pharmaceutical Company, a clinical-stage pharmaceutical company focused on autoimmune and inflammatory disorders, announced positive interim antibody results from its ongoing double-blind, placebo-controlled randomized phase III trial of Riquent® (abetimus sodium), its drug candidate for the treatment of renal disease in patients with systemic lupus erythematosus (SLE).
Wednesday Mar 07, 2007
Evotec and Interprotein Sign Collaboration Agreement to Develop Small Molecule Interleukin-6 Inhibitors to Treat Inflammatory Diseases
Evotec AG, a leader in the discovery and development of small molecule drugs, and Interprotein Corporation, a developer of orally bioavailable small molecule drugs that modulate protein-protein interactions, announced that they have signed a collaboration agreement on Interprotein's interleukin-6 (IL-6) inhibitors program for the development of novel, orally active drugs for the treatment of inflammatory diseases...
Monday Mar 05, 2007
La Jolla Pharmaceutical Company Implements Several Modifications and Updates Status of Phase III Riquent® Study for the Treatment of Lupus Renal Disease
La Jolla Pharmaceutical Company (SAN DIEGO, California) announced its continued progress in enrolling patients in its phase III clinical trial of Riquent® (abetimus sodium) for the treatment of lupus renal disease.
Wednesday Feb 28, 2007
Abbott's HumiraR (Adalimumab) Receives FDA Approval for Self-Administered Treatment of Moderate-to-Severe Crohn's Disease; Represents 4th FDA Approval in Immune-Mediated Diseases for Humira
Abbott announced it has received US FDA approval to market Humira® (adalimumab, a fully human anti-TNF-α monoclonal antibody) as a treatment for reducing the signs and symptoms and inducing and maintaining clinical remission of moderately-to-severely active Crohn's disease (CD) in adults who have had an inadequate response to conventional therapy...
Tuesday Feb 13, 2007
SRI and Telik Announce Exclusive License for SRI to Develop MCP-1 Antagonist for Autoimmune and Inflammatory Diseases
Telik, Inc, a biopharmaceutical company dedicated to discovering, developing, and commercializing novel small molecule drug candidates, and SRI International, an independent nonprofit research and development organization, announced that they have signed an exclusive license agreement...
Monday Jan 29, 2007
Renovis Reduces Workforce by 40%; Will Focus on Inflammatory Diseases and Pain
Renovis, Inc (SOUTH SAN FRANCISCO, California), a biopharmaceutical company that seeks to discover, develop, and commercialize therapeutics for inflammatory and neurological diseases, announced it has reduced its workforce by approximately 40% to approximately 70 employees.
Monday Jan 29, 2007
High MBL Levels Associated With Ischemic Heart Disease in RA
An altered form of IgG found in many RA patients can bind to mannose-binding lectin (MBL), and the resulting immune complexes may explain why high serum levels of MBL increase myocardial infarction risk and ischemic heart disease mortality in RA...
Wednesday Jan 17, 2007
Genzyme's Cerezyme Improves Bone Mineral Density in Patients With Type 1 Gaucher Disease
Genzyme Corporation (CAMBRIDGE, Massachusetts) announced that long-term use of Cerezyme® (imiglucerase for injection) significantly improves bone mineral density (BMD) in patients with Type 1 Gaucher disease in a dose-dependent manner. Cerezyme, an enzyme replacement therapy, is the standard of care for patients with Type 1 Gaucher disease who are at increased risk for developing bone complications, including osteopenia, osteoporosis, and fractures...
Wednesday Jan 10, 2007
Osiris Receives US FDA Fast Track Status for Prochymalâ„¢ Stem Cell Therapy and Clearance to Start Phase III Clinical Trial in Treatment-Resistant Crohn's Disease
Osiris Therapeutics, a leader in adult stem cell therapy, announced that Prochymalâ„¢, a preparation of mesenchymal stem cells obtained from the bone marrow of healthy adult donors and specially formulated for intravenous infusion, has received fast-track designation from the US FDA, expediting the development of the stem cell treatment for Crohn's disease that does not respond to standard therapies.
Monday Jan 08, 2007
MedImmune In-Licenses from Japan Tobacco anti-ICOS Monoclonal Antibody for Inflammatory Diseases
MedImmune, Inc announced an exclusive license agreement with Japan Tobacco, Inc (JT), for a human monoclonal antibody inhibiting inducible costimulator (ICOS), a protein associated with T-cell activation that plays a key role in controlling adaptive immune responses.
Thursday Jan 04, 2007
FivePrime Signs Collaborative Research and License Deal With Centocor to Discover Therapeutics to Treat OA and Other Diseases
FivePrime Therapeutics, Inc, a privately held protein therapeutics discovery and development company, announced the signing of a worldwide collaborative research and license agreement with Centocor, Inc, a wholly owned subsidiary of Johnson & Johnson, to discover therapeutic products to treat osteoarthritis (OA) and pulmonary fibrosis.
Tuesday Dec 12, 2006
ChemoCentryx Releases Additional Clinical and Preclinical Data on Traficet-EN in Inflammatory Bowel Disease; Clinical Analysis Shows that Traficet-EN Reduces Inflammation
ChemoCentryx, Inc (MIAMI, Florida), a privately held, clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing orally-administered therapeutics that target the chemokine and chemoattractant systems in order to treat autoimmune diseases, inflammatory disorders, and cancer, announced new data from a phase II clinical trial of its lead drug candidate Traficet-ENR (CCX282-B, a first-in-class, orally active, anti-inflammatory agent that targets the chemokine receptor known as CCR9) in patients with moderate-to-severe Crohn's disease (CD).
Monday Nov 06, 2006
Array BioPharma Reports Success in Two Approaches to Inflammatory Disease: MEK Inhibitor Achieves Phase I Clinical Objectives; p38 MAP Kinase Inhibitor Advances into Clinical Development
Array BioPharma Inc. (BOULDER, Colorado), a biopharmaceutical company focused on the discovery, development, and commercialization of orally active, small molecule drugs for the treatment of inflammatory diseases and cancer, announced preliminary results from a phase I clinical trial evaluating its first-in-class MEK (MAPK kinase) inhibitor for the treatment of inflammatory diseases.
Monday Oct 23, 2006
Osiris Reports Positive Initial Results from Pilot Phase II Study of its Prochymalâ„¢ Stem Cell Therapy in Treatment-Resistant Crohn's Disease
Osiris Therapeutics, a leader in adult stem cell therapy, announced positive results from a pilot 10-patient phase II study using Prochymalâ„¢, an intravenous formulation of mesenchymal stem cells obtained from the bone marrow of healthy volunteer donors, for the treatment of patients with moderate to severe Crohn's disease (CD) who had failed to respond to standard treatments, such as steroids and infliximab (RemicadeR, Centocor, Inc).
Thursday Oct 19, 2006
Lexicon Genetics Initiates Formal Preclinical Development for LX2931 for Autoimmune Disease
Lexicon Genetics Incorporated, an emerging biopharmaceutical company employing its proprietary gene knockout technology to discover knockout-validated drug targets, announced that it is initiating formal preclinical development for LX2931 in preparation for an Investigational New Drug (IND) application.
Wednesday Oct 18, 2006
Rigel Selects a Novel JAK3 Inhibitor for Advanced Preclinical Development for Immune-Mediated Diseases
Rigel Pharmaceuticals, Inc., a clinical-stage drug development company focused on small-molecule drugs for the treatment of inflammatory/autoimmune diseases, cancer, and viral diseases, announced that it has selected R348, a potent and selective inhibitor of janus tyrosine kinase 3 (JAK3), to enter preclinical studies to support an investigational new drug application planned for 2007...
Thursday Oct 12, 2006
MRI Predicts Which Children with Monoarthritis Will Develop Aggressive Disease
MRI scans of clinically unaffected knees in children with monoarthritis can predict who will develop widespread joint disease within the next year... Gardner-Medwin JM, et al. J Rheumatol. 2006; 15 Sept; [Epub ahead of print]
Tuesday Oct 10, 2006
Novogen's Isoflavonoid Investigational Drug for Inflammatory Bowel Disease Enters Phase Ib Clinical Trial
Novogen Limited announced that its investigational anti-inflammatory compound NV-52, an isoflavonoid-based drug candidate, is entering its second human clinical study following the successful completion of toxicology testing...
Monday Oct 02, 2006
La Jolla Pharmaceutical to Expand Number of Clinical Trial Sites for Its Phase III International Trial of Riquent for the Treatment of Lupus Renal Disease
La Jolla Pharmaceutical Company (SAN DIEGO, Calif.), a biotechnology company developing therapeutics for antibody-mediated autoimmune diseases and inflammation, announced progress and the expansion of its phase III trial of Riquent® (abetimus sodium, previously referred to as LJP 394) for the treatment of lupus renal disease, a leading cause of sickness and death in patients with lupus.
Thursday Sep 28, 2006
RA Skin Problems Related or Due to Disease or Treatment?
Skin problems are more common in RA patients than in those with non-inflammatory diseases, but only steroid-related bruising and athlete's foot appear to be related to either RA itself or its treatment.
Tuesday Sep 26, 2006
Can-Fite BioPharma Licenses Its A(3) Adenosine Receptor Agonist (CF101) to Seikagaku to Develop and Market in Japan for Inflammatory diseases
Can-Fite BioPharma Ltd, a clinical-stage drug development company focused on a portfolio of orally bioavailable, highly selective, small-molecule A(3) adenosine receptor (A3AR) agonists with potent activities in inflammation and cancer, announced that it has signed an exclusive license agreement with a Japanese research-based pharmaceutical company, Seikagaku Corporation, to develop and market its lead orally bioavailable A3AR agonist, CF101 (1-deoxy-1-(6-[([3-iodophenyl] methyl) amino]-9H-purin-9-yl)-N-methyl-β-d-ribofuranuronamide), in Japan for the treatment of inflammatory indications including rheumatoid arthritis (RA) but not including ophthalmic indications.
Monday Sep 25, 2006
Rituximab Quickly Reduces Disease Activity in Treatment-Resistant RA
Rituximab added to methotrexate significantly reduces disease activity in patients whose RA is resistant to TNF inhibitors... Cohen SB, et al. Arthritis Rheum. 2006;54:2793-2806.
Thursday Sep 21, 2006
Avidia Initiates Clinical Trial of Avimerâ„¢ C326, an Inhibitor of Interleukin-6, for Crohn's Disease
vidia, Inc., a privately-held biopharmaceutical company focused on discovering and developing a new class of small, assembled human therapeutic proteins called Avimersâ„¢ (from avidity multimers), announced that it has initiated dosing of the first patient for a phase I clinical trial of its Avimer drug candidate C326, an inhibitor of interleukin-6 (IL-6), for the treatment of Crohn's disease.
Tuesday Sep 19, 2006
Predix (now known as EPIX) Signs Exclusive Collaboration and License Agreement with Amgen, Potentially Worth Over $307.5 Million, for the Development of S1P1 Modulators for Treatment of Autoimmune Diseases; Predix Completes Merger with EPIX
Predix Pharmaceuticals Holdings, Inc. announced an exclusive collaboration and licensing deal with Amgen to develop Predix's existing preclinical and new, orally available S1P1 modulators for autoimmune diseases.
Tuesday Sep 12, 2006
BioLineRx In-Licenses Novel Antisense Drug for the Treatment of Inflammatory Diseases
BioLineRx announced that it has signed an exclusive worldwide license agreement with B.G. Negev Technologies Ltd., the technology transfer company of Ben-Gurion University of the Negev, and Mor Research Applications, Ltd., the Technology Transfer Office of Clalit Health Services, for the development and commercialization of BL-3030, a novel antisense drug inhibiting the formation of the enzyme cPLA2 (cytosolic phospholipase A2)for the treatment of inflammatory diseases...
Monday Sep 11, 2006
Abbott Seeks US and EU Approvals for HUMIRA (Adalimumab) for Crohn's Disease
Abbott announced it has simultaneously submitted a supplemental Biologics License Application with the US FDA and a Type II Variation to the European Medicines Agency seeking approval to market HUMIRAR (adalimumab) as a treatment for moderate-to-severe Crohn's disease...
Thursday Aug 31, 2006
Genizon Grants Exclusive License for Crohn's Disease GeneMap to Genentech
Genizon BioSciences, a gene and drug target discovery company, announced a license and collaboration agreement with Genentech, Inc. under which Genizon granted Genentech an exclusive license to Genizon's GeneMap of disease-associated genes generated from a whole genome association study of Crohn's disease patients from the Quebec Founder Population...
Monday Aug 28, 2006
GlaxoSmithKline and ChemoCentryx Establish Worldwide Strategic Alliance to Develop Therapies for Inflammatory and Autoimmune Diseases; ChemoCentryx May Pocket More Than $1.5 Billion, Raises $17.7 Million in Series C Financing
GlaxoSmithKline and ChemoCentryx, Inc., a company focused on orally-administered, small-molecule therapeutics that target the chemokine and chemoattractant receptor systems, announced a worldwide multitarget strategic alliance to discover, develop, and market novel medicines targeting four chemokine and chemoattractant receptors for the treatment of a variety of inflammatory disorders, including inflammatory bowel disease (IBD), rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), multiple sclerosis (MS), acute macular degeneration, and asthma...
Wednesday Aug 16, 2006
Biogen Idec and University of Adelaide Find TWEAK Is a Novel Arthritogenic Mediator; Potential New Pathway in Rheumatoid Arthritis and Osteoarthritis Disease Process
Biogen Idec announced studies published in the August 15, 2006, issue of the providing evidence that TWEAK (TNF-like weak inducer of apoptosis), a TNF family member, is a novel arthritogenic mediator that contributes to joint tissue inflammation, angiogenesis, and destruction, and may inhibit endogenous repair.
Monday Aug 14, 2006
TissueGene Initiates Phase I Study of TissueGene-C in Patients With Degenerative Joint Disease of the Knee Prior to Total Knee Arthroplasty
TissueGene, Inc. announced the initiation of a phase I clinical trial of the company's cell-mediated therapy, TissueGene-C (TG-C).
Wednesday Aug 02, 2006
Schering AG Obtains Mixed Results From Two Clinical Trials of Sargramostim for Crohn's Disease: Phase III Fails to Achieve Primary End Points; Phase II Meets Primary and Secondary Endpoints
Schering AG, Germany announced results from two recently completed multicenter, placebo-controlled, randomized, double-blind clinical studies of sargramostim for the treatment of Crohn's disease.
Wednesday Jul 19, 2006
TeGenero Files for Insolvency as Investors Evaporate Following Disastrous First-In-Man Phase I Trial of Superagonistic Anti-CD28 Antibody for Autoimmune Diseases and Leukemia
TeGenero AG has filed for the commencement of insolvency proceedings at the competent local court/insolvency court because the serious adverse reactions caused by the investigational agent TGN1412 in the March 2006, first-in-man, phase I trial made it impossible to attract the investment necessary for the company to continue operations.
Wednesday Jul 19, 2006
Metabolic Syndrome Correlates With High Disease Activity in RA
Metabolic syndrome correlates with higher disease severity in RA. Karvounaris SA, et al. Ann Rheum Dis; published online June 22, 2006.
Monday Jul 17, 2006
LTKfarma Starts Operations With Lead Product for Autoimmune Diseases and Leukemia Already in Phase I/II, Names Advisory Board
LTKfarma, a biopharmaceutical company founded in March 2006 and focused on developing and marketing cell therapy products derived from modified T-cells to treat autoimmune diseases and leukemia announced its creation and the appointment of its advisory board....
Friday Jun 30, 2006
Consider Disease Duration in Comparing Functional Outcomes of RA Treatment
Measures of physical function such as the HAQ become less responsive to treatment effects with increasing duration of RA, so disease duration should be considered in comparing functional outcomes of different treatments...Aletaha D. 2006 EULAR Meeting.
Tuesday Jun 27, 2006
Entremed's 2ME2 Demonstrates Antiangiogenic Activity in Rat Model of Chronic Autoimmune Inflammatory Joint Disease
EntreMed, Inc., a clinical-stage pharmaceutical company developing therapeutics for the treatment of inflammatory diseases and cancer, announced the presentation of preclinical data for its lead compound, 2-methoxyestradiol (2ME2), in rheumatoid arthritis (RA)....
Monday Jun 19, 2006
PDL's Nuvion® Humanized Anti-CD3 T-Cell Receptor Antibody Active in Crohn's Disease, Ulcerative Colitis
PDL BioPharma, Inc, of Fremont, California, announced that new data from studies of Nuvion® (visilizumab, a humanized low FcR-binding IgG2 anti-CD3 monoclonal antibody) in Crohn's disease and ulcerative colitis were presented at the annual Digestive Disease Week meeting...
Saturday Jun 10, 2006
Regeneron's IL-1 Trap Receives Fast-Track Designation from US FDA for CIAS1-Associated Periodic Syndromes (CAPS), a family of rare autoinflammatory diseases
Regeneron's IL-1 Trap Receives Fast-Track Designation from US FDA for CIAS1-Associated Periodic Syndromes (CAPS), a family of rare autoinflammatory diseases
Friday Jun 09, 2006
Cytopia Signs Exclusive License and Collaboration Agreement With Novartis for JAK3 Kinase Inhibitors in Autoimmune Diseases and Transplant Rejection
Cytopia Ltd announced the execution of a worldwide license and R&D collaboration agreement with Novartis to develop orally active, small-molecule therapeutics targeting JAK3 kinase...
Thursday Jun 01, 2006
Ocera's AST-120 Improves Anal Fistulas, Begins Phase III Trial in Fistulizing Crohn's Disease
Ocera Therapeutics, Inc, announced the first North American and European pivotal phase III clinical trial of AST-120 in patients with mild to moderate fistulizing Crohn's disease...
Wednesday May 24, 2006
Centocor's RemicadeR Approved by US FDA for Pediatric Crohn's Disease
Centocor Inc announced US FDA approval of Remicade® (infliximab) for reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients with moderately to severely active Crohn's disease...
Wednesday May 17, 2006
Immunomedics and UCB Announce Collaboration and License Agreement for Epratuzumab for Autoimmune Diseases
Immunomedics, Inc, and UCB announced a development collaboration and license agreement for Immunomedics' lead product, epratuzumab...
Wednesday May 17, 2006
Avidia Raises $43.8 Million in Series C Financing to Advance Its Lead Avimerâ„¢ Drugs for Inflammation and Autoimmune Diseases
Avidia, Inc, announced that it has raised $43.8 million in a Series C financing round...
Monday May 08, 2006
Array BioPharma Initiates Phase I Clinical Trial of Its MEK Inhibitor for Inflammatory Disease
Array BioPharma Inc, of Boulder, Colorado, announced the initiation of a phase I clinical trial in the US for its proprietary small-molecule novel MEK inhibitor, ARRY-438162, for the treatment of inflammatory disease...
Wednesday May 03, 2006
FivePrime Inks Research and License Deal With Boehringer Ingelheim to Discover New Therapeutics to Treat RA and Other Diseases
FivePrime Therapeutics, Inc, of San Francisco, California, announced a 2-year collaborative research and license agreement with Boehringer Ingelheim...
Friday Apr 14, 2006
Centocor's Remicade® Designated for Priority Review by FDA for Pediatric Crohn's Disease
Centocor, Inc, of Horsham, Pennsylvania, announced that the supplemental Biologics License Application (sBLA) for Remicade® (infliximab)...
Tuesday Apr 11, 2006
PanGenetics Closes $15.6M in Series B Financing to Advance CD40 Antagonist in Autoimmune Disease
PanGenetics BV has closed a €13 million ($15.6 million) second round of financing to advance clinical development of its lead drug candidate PG102, a human CD40 antagonist...
Monday Mar 20, 2006
Trial Halted of TeGenero's Study Drug TGN1412 (CD28-SuperMAB®) for Autoimmune Diseases and Leukemia; Six Hospitalized Following Serious Adverse Reactions
TeGenero AG, of Würzburg, Germany, announced that six subjects participating in a clinical trial evaluating the safety of its study drug TGN1412...
Monday Mar 06, 2006
Trubion Eligible to Receive Over $800 Million in Milestone Payments From Wyeth in Strategic Alliance to Co-develop and Commercialize Trubion's SMIPâ„¢ Technology for Inflammatory Disease and Cancer
Trubion Pharmaceuticals, Inc, of Seattle, Washington, and Wyeth of Madison, New Jersey, announced that they have formed a strategic alliance for the discovery, development, and commercialization of novel SMIPâ„¢ biologics...
Thursday Feb 23, 2006
Roche Initiates Clinical Study for Bone-Related Disease Using Emisphere's Oral Formulation Drug Delivery (Eligen®) Technology
Emisphere Technologies, Inc, of Tarrytown, New York, announced that it has received an undisclosed payment from Roche Pharmaceuticals...
Thursday Feb 23, 2006
G2 Inflammation Pty Ltd Signs Deal With Novo Nordisk for Anti-C5a Receptor Antibody for the Treatment of RA and Other Inflammation-Mediated Diseases
G2 Inflammation Pty Ltd (G2I) announced a research, development, and licensing agreement with the Danish healthcare company Novo Nordisk to advance G2's Neutrazumab...
Thursday Feb 23, 2006
EntreMed Receives New Patent for 2-Methoxyestradiol (2ME2, or Panzem®) Analogs for Inflammatory Diseases
EntreMed, Inc, of Rockville, Maryland, announced the issuance of US Patent No. 6,995,278, covering compositions and methods for treating mammalian diseases characterized by undesirable angiogenesis, by administering derivatives of 2-methoxyestradiol...
Tuesday Feb 14, 2006
Disease Activity and Severity Seen as Determinants in Starting Tumor Necrosis Factor-Alpha Blockers in Ankylosing Spondylitis Prior to Publication of ASAS Recommendations
Both disease activity and severity were determinants in starting tumor necrosis factor-alpha blockers in ankylosing spondylitis patients prior to the publication of the 2003 Assessment in AS (ASAS) international working group recommendations... Pham T, et al. Ann Rheum Dis [serial online]. February 7, 2006; doi:10.1136/ard.2005.042630
Monday Feb 06, 2006
NovImmune Files IND Application in Netherlands for Fully Human Antibody Against CD3 for Autoimmune Disease
Medarex, Inc, of Princeton, NJ, has announced the filing of an Investigational New Drug (IND) application in the Netherlands by its licensing partner, NovImmune SA of Geneva, Switzerland, for NI-0401...
Friday Jan 27, 2006
Phosphodiesterase Type 5 Inhibition Improves Raynaud's Disease
New research adds to evidence that because of their vasodilatory properties, phosphodiesterase type 5 inhibitors may be a useful therapeutic option for the treatment of Raynaud's disease... Caglayan E, et al. Arch Intern Med. 2006;166:231-233.
Friday Jan 20, 2006
Patients with Chronic Skin Disease Who Require Long-Term Corticosteroids Not Receiving Bisphosphonates
Most patients who receive prolonged oral corticosteroids for chronic skin diseases such as pemphigus vulgaris and cutaneous lupus erythematosus are not receiving bisphosphonates... Liu RH, et al. Arch Dermatol. 2006;142:37-41.
Wednesday Jan 18, 2006
Illumina, Inc, Has Announced That the NIDDK Inflammatory Bowel Disease Genetics Consortium Will Perform a Genome-Wide Survey to Identify Genetic Variants That Increase Susceptibility to Crohn's Disease
Illumina, Inc, has announced that the National Institutes of Health National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) Inflammatory Bowel Disease Genetics Consortium...
Wednesday Jan 04, 2006
Oral Calcitonin May Delay Onset of Joint Disease and Relieve Pain of OA
Although calcitonin is an established antiresorptive agent, new research suggests that it also has a role in chondroprotection and may help relieve symptoms accompanying joint disease... Sondergaard BC, et al. Presented at: 10th World Congress of the Osteoarthritis Research Society International (OARSI); December 8–11, 2005; Boston, Mass. Abstract P133.
Wednesday Jan 04, 2006
Synta to Advance Clinical Development of IL-12/IL-23 Inhibitor for Crohn's Disease and RA
Synta Pharmaceuticals of Lexington, Massachusetts, announced that it will focus its clinical development efforts in 2006 on STA-5326, an oral interleukin (IL)-12/IL-23 inhibitor...
Tuesday Dec 13, 2005
Osiris to Initiate Phase II Trial of Prochymalâ„¢ for Crohn's Disease
Osiris Therapeutics, Inc, of Baltimore, Maryland, has announced the start of enrollment for its phase II clinical trial of Prochymalâ„¢...
Monday Dec 05, 2005
Roche and BioCryst Collaborate on Phase I Compound for Autoimmune Diseases and Transplant Rejection
Roche Pharmaceuticals of Nutley, New Jersey, and BioCryst Pharmaceuticals, Inc, of Birmingham, Alabama, have announced...
Monday Nov 21, 2005
New Analysis Supports La Jolla Pharmaceutical's Riquent® for Lupus Renal Disease; Company Reports on Experimental Anti-inflammatory Agent
La Jolla Pharmaceutical Co of San Diego, California, announced that new analyses of existing clinical trial data provide support for Riquent® (abetimus sodium)...
Thursday Nov 17, 2005
A 35-Year Look at SLE: Lower Mortality and Milder Disease at Presentation
Despite the absence of a new therapy for systemic lupus erythematosus (SLE) in the past 30 years, mortality from SLE and disease activity at presentation are declining—findings that may be attributed in part to the greater use of immunosuppressive agents and lower steroid doses... Urowitz MB, et al. Presented at: Annual Meeting of the American College of Rheumatology; November 12–17, 2005; San Diego, Calif.
Wednesday Nov 16, 2005
Osteoporosis Drug Risedronate May Have Disease-Modifying Effects in Osteoarthritis
High doses of risedronate (Actonel®) may protect against subchondral bone loss in knee osteoarthritis patients with progressive joint space narrowing... Presented at: Annual Meeting of the American College of Rheumatology; November 12–17, 2005; San Diego, Calif.
Wednesday Nov 16, 2005
Chromos to Acquire Target Molecules Corporation and Its Anti-VLA-2 Product Candidate for Inflammatory Diseases; Complete a $6–10 Million Private Placement
Chromos Molecular Systems Inc of Burnaby, British Columbia, Canada, has announced that it will acquire Target Molecules Corporation of San Diego, California, a privately held biotechnology company with two preclinical stage antibody product candidates, including TMC-2003
Monday Nov 07, 2005
Positive Phase III Results for Remicade® in Pediatric Crohn's Disease Drives Fast Track Designation for Indication
Centocor, Inc (Horsham, Pa.), announced at the 18th Annual Meeting of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition...
Monday Oct 24, 2005
La Jolla Pharmaceutical Secures Funding to Commence Re-enrollment of Phase III Trial of Riquent® for Lupus Renal Disease
La Jolla Pharmaceutical Corporation of San Diego, California, announced that it has entered into an agreement...
Tuesday Oct 18, 2005
Fatigue in Lupus Linked to Depression and Pain, but Often Missed by Standard Disease Assessment Tools
New research suggests that depression, pain, and perceived lack of social support are often-overlooked predictors of fatigue in patients with systemic lupus erythematosus (SLE)—findings that may lead to a better understanding of psychosocial factors and a more specific therapeutic target for the treatment of this debilitating disease... Jump RL, et al. J Rheumatol. 2005;32:1699-1705.
Monday Oct 17, 2005
Autoimmune Disease May Contribute to Increase in Non-Hodgkin's Lymphoma, Particularly Among Women
Providing further insight into the dramatic rise in the incidence of non-Hodgkin's lymphoma (NHL) over the last 20 years, a new study suggests that autoimmune diseases, as well as the potent immunosuppressive drugs commonly used for their treatment, may partly account for the increase in NHL, especially among women... Cuttner J, et al. J Rheumatol. 2005;32:1884-1887.
Friday Oct 07, 2005
Novel Population of T Cells Found to Produce IL-17; In Vivo Analysis Reveals Role of Cytokine in Inflammatory Disease
New research examining the production and function of the inflammatory cytokine interleukin 17 (IL-17) may pave the way for more effective ways to prevent and treat rheumatoid arthritis (RA) and other autoimmune and inflammatory conditions . . . Nat Immunol [serial online]. October 2, 2005.
Wednesday Sep 21, 2005
Low-Dose Safer Than High-Dose Steroids in Rheumatoid Arthritis
A new literature review suggests that the toxicity associated with glucocorticoids is largely a result of higher doses, a finding that may serve to restore greater use of long-term, low-dose glucorticoid therapy in rheumatoid arthritis (RA)... Da Silva JAP, et al. Ann Rheum Dis [serial online]. August 26, 2005.
Tuesday Sep 13, 2005
Two New Treatments Show Promise in Paget's Disease
Zoledronic acid and osteoprotegerin found to be promising new therapies for the management of Paget's disease... Reid IR, et al. N Engl J Med. 2005;353:898-908; Cundy MD, et al. N Engl J Med. 2005;353:918-923.
Thursday Sep 08, 2005
Cyclophosphamide/Stem Cell Transplantation Protocol Shows Promise for Refractory Autoimmune Diseases
Japanese researchers report promising phase I-II trial results showing that high-dose cyclophosphamide supported by autologous peripheral blood stem cell transplantation is feasible and may be effective in the treatment of severe and refractory autoimmune diseases such as systemic sclerosis and SLE...Tsukamoto H, et al. Ann Rheum Dis online August 26, 2005
Wednesday Aug 17, 2005
Elevated CRP May Predict Cardiovascular Disease Mortality in RA Patients
New research augments the growing body of evidence suggesting that the inflammation of RA causes premature atherosclerosis... Goodson NJ, et al. Arthritis Rheum. 2005;52:2293-2299.
Wednesday Aug 10, 2005
Abatacept Reduces Disease Activity and Improves Function in RA Patients Who Failed MTX
Results of a 12-month study show that the first in a class of agents designed to block a costimulatory pathway required for optimum activation of T cells may play an important role in the treatment of rheumatoid arthritis (RA), particularly among patients unresponsive to methotrexate (MTX)... Kremer JM, et al. Arthritis Rheum. 2005;52:2263-2271.
Sunday Jul 31, 2005
UCB's Cimzia Demonstrates Positive Results in Phase III Trials for Crohn's Disease
USB Pharma, Inc, of Atlanta, Georgia, the biopharmaceutical subsidiary of international pharmaceutical...
Thursday Jun 30, 2005
Doxycycline Slows Osteoarthritis Disease Progression
New study results confirm preclinical data suggesting that doxycycline can slow joint space narrowing in the medial tibiofemoral compartment in knee osteoarthritis, but the common antibiotic did not affect pain...Brandt K, et al. Arthritis Rheum. 2005;52:2015-2025
Wednesday Jun 22, 2005
Early Ankylosing Spondylitis Cohort Underscores Link Between Sustained Disease Activity and Progression
German Spondyloarthritis Inception Cohort (GESPIC) shows that sustained high disease activity during the early stages of AS, despite treatment with NSAIDs, may be an important prognostic indicator of disease progression, and may suggest a possible earlier role for TNF-blockade... Presented at: European Congress of Rheumatology of EULAR; June 8-11, 2005; Vienna, Austria.
Monday Jun 13, 2005
Smokers Have More Active Rheumatoid Arthritis Than Nonsmokers, but Quitting May Help Reduce Disease Severity
New research presented at EULAR increases our understanding of how smoking impacts RA, and emphasizes the symptomatic benefits for those who stop...presented at: Annual European Congress of Rheumatology of EULAR; June 8-11, 2005; Vienna, Austria.
Thursday Jun 09, 2005
AVANIR/Novartis Agreement: Develop MIF Therapies for Inflammatory Diseases
AVANIR Pharmaceuticals, a drug discovery and development company, announced the signing of an agreement with Novartis Pharmaceutical Corp to develop orally active small molecule therapeutics targeting macrophage migration inhibitory factor (MIF), a proinflammatory cytokine that is thought to play a critical role in the pathology of inflammatory diseases such as rheumatoid arthritis, psoriasis, and inflammatory bowel disease.
Friday Jun 03, 2005
Recombinant Version of Alpha-Fetoprotein May Hold Promise in RA and Other Autoimmune Diseases
As a Phase II trial begins, experts are cautiously optimistic that the experimental immunomodulating agent may be safer than existing RA treatments, and that the work may help explain why RA tends to remit during pregnancy...National Jewish Medical and Research Center [press release]; June 2, 2005.
Wednesday Jun 01, 2005
More Evidence for the 'FitzGerald Hypothesis' on the Relationship of Coxibs and Cardiovascular Disease Risk
Vascular remodeling may interact with a predisposition to hypertension and atherosclerosis, contributing to the gradual increase in cardiovascular risk during extended periods of treatment with COX-2 inhibitors...Rudic RD, et al. Circ Res. Published online May 19, 2005.
Friday May 20, 2005
Study Provides Clues to the Mechanism of Remission of Inflammatory Diseases During Pregnancy
Analysis of pro- and anti-inflammatory cytokines in pregnant women with rheumatoid arthritis, juvenile idiopathic arthritis, and ankylosing spondylitis may help provide a better understanding as to why certain rheumatic diseases improve during pregnancy...Ostensen M, et al. Ann Rheum Dis. 2005;64:839-844
Thursday May 12, 2005
Genmab and Serono Partner on HuMax-TAC for T Cell-Mediated Diseases
Genmab A/S granted Serono S.A. exclusive worldwide rights to develop and commercialize Genmab's HuMaxR-TAC, a preclinical fully humanized monoclonal antibody targeting the TAC antigen. The TAC antigen, also known as CD25 or the interleukin-2 receptor alpha subunit (IL-2R±), is overexpressed by activated T-cells. By inhibiting T-cell proliferation, HuMax-TAC may have therapeutic potential in the treatment of T cell-mediated diseases such as autoimmune and inflammatory disorders and hyperproliferative skin conditions. Genmab will receive an upfront payment of $2 million, potential milestone payments of up to $38 million, and royalties on product sales. Serono will be responsible for all future development costs for HuMax-TAC.
Wednesday May 11, 2005
New Genetic Variant May Increase Risk of Inflammatory Disease
A recently identified polymorphism results in differential HLA molecule expression and is associated with susceptibility to common diseases with inflammatory components...Swanberg M, et al. Nat Genet. 2005;37:486-494.
Thursday Apr 21, 2005
Novel PAR-2 Antagonists Developed for Inflammatory Disease and Cancer
Preclinical studies conducted by EntreMed, Inc, indicate that its proteinase activated receptor (PAR-2) antagonists not only inhibit tumor growth and the formation of new blood vessels in animal models, but also block inflammation in preclinical rheumatoid arthritis and in models of acute inflammation. The new data were presented at the American Association for Cancer Research annual meeting in Anaheim, California.
Friday Mar 18, 2005
Study Suggests Celiac Disease May Be More Prevalent Among Patients with Osteoporosis
New results confirm the value of treating osteoporotic patients with the disease and fuel the debate over the practicality of widespread screening... Stenson WF, et al. Arch Intern Med. 2005;165:393-399.
Friday Feb 04, 2005
Rheumatoid Arthritis Patients Face Higher Risk for Congestive Heart Failure and Unrecognized Coronary Heart Disease
Two population-based studies suggest that the heightened risk of heart disease may be attributed to the systemic inflammation that characterizes RA rather than traditional risk factors&Nicola PJ. Arthritis Rheum. 2005;52:412-420; Maradit-Kremers H. Arthritis Rheum. 2005;52:402-411.
Thursday Feb 03, 2005
Crohn's Disease Patients With Attenuated Response to Infliximab May Respond to Adalimumab
Mimicking the paradigm seen with TNF-blockade in rheumatoid arthritis, preliminary data suggest that switching infliximab nonresponders to adalimumab may improve the clinical response and reduce disease activity...Papadakis KA. Am J Gastroenterol. 2005;100:75-79.
Monday Dec 13, 2004
Synovial Tissue Interleukin-18 Expression Correlates With Inflammatory Arthritis Disease Activity
New study underscores the important proinflammatory role of IL-18 in the pathophysiology of inflammatory arthritis, and suggests that treatment that inhibits or neutralizes endogenous IL-18 may become an effective tool in controlling synovial tissue inflammation&Rooney T, et al. Ann Rheum Dis. 2004;63:1393-1398.
Tuesday Oct 12, 2004
Combination Step-Down Regimen Enhances Disease Control Over Sulfasalazine Monotherapy for RA, Without Adding Cost
A combination regimen consisting of prednisolone, methotrexate, and sulfasalazine may produce more robust clinical responses at equal or lower cost than sulfasalazine alone for the treatment of early rheumatoid arthritis... Korthals-de Bos I et al. J Rheumatol. 2004;31:1709–1716.
Monday Aug 30, 2004
Incidence of Gout Increasing; New Therapies Have Promise to Make Disease More Manageable
(Bieber JD, Terkeltaub RA, et al. Arthritis Rheum. 2004;50:2400-2414.)
Thursday Jun 10, 2004
Pregnancy and Autoimmune Disease: Balance Risk of Disease versus Treatment to Fetus
Physicians who treat patients with autoimmune disease need to consider the risks of the disease to pregnancy and fertility as well as the treatment.
|
